Interbank lending remains stable

Interbank confidence stood firm today after a tumultuous day on the world equity markets.

In the overnight markets, dollar Libor was the worst casualty, climbing 26 basis points to 0.7%. Sterling Libor stayed at 300bp and euro Libor dropped marginally to 2.89% from 2.9% yesterday.

Three-month dollar Libor increased by a basis point to 2.16%, while three-month sterling and euro Libor fell to 4.04% from 4.1% and to 4% from 4.06% respectively.

The Ted spread, which measures perceived counterparty risk by tracking the difference between three-month Libor and US Treasury bills, increased by a basis point to 2.12% as of 1710 GMT today.

The Chicago Board Options Exchange Vix volatility index, which measures the implied volatility of Standard & Poor's 500 index options, stood at 76.29 at 1710 GMT, having dropped from yesterday's close of 80.74.

European equity markets continued to suffer today. Both France's Cac 40 and Germany's Dax index recorded year lows for the second day running, closing at 2881.26 and 4127.41 respectively.

London's FTSE 100 index also plummeted to a year low at close of trading, falling 2.4% to 3780.96.

In the US, markets showed signs of recovery in early trading. As of 1745 GMT, the S&P 500 index had climbed 1.81% to 766.05.

In the Asian markets, Japan's Nikkei 225 closed today at 7910.79, a gain of 2.7%, while Hong Kong's Hang Seng index closed at 12659.20, an increase of 2.93%.

See also: US CDSs continue to soar as eurozone banks stabilise
Libor untouched by market turbulence

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here